HSIC vs MDLN vs AMRX Stock Comparison

Henry Schein, Medline and Amneal Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
HSIC Henry Schein Inc
$86.22 +0.8% 1M +17.6% 1Y
Market cap
$9.36B
P/E
22.2x
Revenue (TTM)
$13.73B
Div. yield
0.00%
Drug Distribution Healthcare
3 wins
MDLN Medline Inc.
$39.47 +9.9% 1M
Market cap
$34.27B
P/E
40.8x
Revenue (TTM)
$30.68B
Div. yield
–
Medical Supplies Healthcare
2 wins

Head to Head

11 decided of 12

Amneal Pharmaceuticals leads on 6 of the 12 questions below (Amneal Pharmaceuticals 6, Henry Schein 3, Medline 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionHSICMDLNAMRXLeader
Larger companyMarket capitalisation $9.36B $34.27B $7.14B MDLN
Cheaper on earningsLower P/E, profitable companies only 22.2x 40.8x 53.6x HSIC
Cheaper on forward earningsLower price / next fiscal year consensus EPS 14.6x 26.5x 21.4x HSIC
Faster revenue growthRevenue growth, trailing twelve months +6.2% — +8.9% AMRX
More profitableNet margin, trailing twelve months 3.1% 2.7% 4.2% AMRX
Better return on capitalReturn on invested capital 7.3% 4.3% 14.3% AMRX
Less leveragedLower net debt / EBITDA 3.2x 3.2x 4.3x MDLN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +17.6% — +85.6% AMRX
Better 5-year returnAnnualised price return, 5 years +1.7%/yr — +32.7%/yr AMRX
Less volatileAnnualised volatility, 1 year 25.2% 47.8% 34.3% HSIC
Higher overall scoreMean of the five percentile scores vs peers 57/100 53/100 69/100 AMRX

Percentile Scorecard

HSICMDLNAMRX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisHSICMDLNAMRX
Valuation 46 #15 of 27 78 #54 of 243 90 #69 of 660
Growth 48 #14 of 26 – 70 #189 of 619
Profitability 76 #7 of 26 73 #60 of 222 87 #80 of 595
Financial Health 20 #21 of 26 43 #143 of 248 11 #606 of 683
Shareholder Returns 94 #2 of 18 17 #132 of 158 89 #53 of 459
Overall 57 53 69
  • HSIC ranked among 27 companies in Healthcare Payers and Distributors
  • MDLN ranked among 252 companies in Medical Devices and Diagnostics
  • AMRX ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodHSICMDLNAMRXSPY
1 month +0.8%+9.9%+13.1% -2.0%
3 months -4.0%+10.4%+17.8% -2.8%
6 months +18.6%+9.1%+79.2% +2.0%
Year to date +14.1%-6.0%+69.7% +10.6%
1 year +17.6%—+85.6% +12.2%
3 years +25.1%—+367.8% +68.1%
3 years, per year +7.8%—+67.3% +18.9%
5 years +8.8%—+310.4% +61.4%
5 years, per year +1.7%—+32.7% +10.1%
10 years +40.3%—— +248.5%
10 years, per year +3.4%—— +13.3%

Risk

MeasureHSICMDLNAMRXSPY
Volatility, 1Y 25.2%47.8%34.3% 13.6%
Downside volatility, 1Y 25.4%48.2%30.7% 13.9%
Beta vs S&P 500, 1Y 0.630.740.67 1.00
Return / volatility, 1Y 0.70—2.49 0.90
Max drawdown, 5Y -32.7%-36.7%-75.4% -25.4%
From 52-week high -5.1%-21.0%-1.5% -3.2%
52-week high $90.86$49.99$21.71 $779.14
52-week low $68.99$31.64$11.52 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleHSICMDLNAMRX
P/E now vs peer median 22.8xmedian 25.2x 41.1xmedian 26.5x 53.8xmedian 17.0x
P/S now vs peer median 0.7xmedian 0.4x 1.7xmedian 2.7x 2.3xmedian 8.4x
EV/EBITDA now vs peer median 12.4xmedian 14.5x 21.6xmedian 18.4x 15.1xmedian 14.6x
P/FCF now vs peer median 17.0xmedian 16.5x 27.4xmedian 25.4x 193.9xmedian 19.0x
P/B now vs peer median 2.5xmedian 2.7x 2.7xmedian 2.5x 14.0xmedian 2.0x
PEG now vs peer median 6.74median 1.72 —median 0.98 0.65median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsHSICMDLNAMRX
Revenue $13.73B $30.68B $3.20B
Gross profit $4.34B $7.90B $1.29B
Operating income $709.00M $1.74B $478.99M
Net income $443.00M $889.00M $175.49M
Free cash flow $559.00M $1.90B $38.42M
R&D – – $180.59M
EPS (diluted) $3.74 $0.64 $0.40
Cash & equivalents $184.00M $2.32B $157.40M
Total debt $3.52B $12.58B $3.12B
Shares (diluted) 112.54M 1.32B 335.73M
Enterprise value $9.18B $23.81B $6.37B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricHSICMDLNAMRX
P/E 22.8x 41.1x 53.8x
P/FCF 17.0x 27.4x 193.9x
P/Operating cash flow 13.9x 21.8x 41.2x
P/S 0.7x 1.7x 2.3x
P/B 2.5x 2.7x 14.0x
P/Tangible book 3.3x 8.6x -7.3x
EV/EBITDA 12.4x 21.6x 15.1x
EV/EBIT 18.2x 35.0x 21.7x
EV/Revenue 0.9x 2.0x 3.3x
EV/FCF 23.0x 32.1x 271.0x
EV/Operating cash flow 18.7x 25.6x 57.6x
PEG (3Y EPS CAGR) 6.74 – 0.65

Growth

14 metrics
MetricHSICMDLNAMRX
Revenue growth (1Y) 6.2% – 8.9%
Revenue CAGR (3Y) 2.7% – 10.2%
Gross profit growth (1Y) 7.5% – 19.2%
Gross profit CAGR (3Y) 3.3% – 15.0%
Operating income growth (1Y) 9.9% – 33.8%
Operating income CAGR (3Y) 3.0% – 28.4%
Net income growth (1Y) 7.5% – 271.2%
Net income CAGR (3Y) -2.0% – 53.6%
EPS growth (1Y) 15.8% – 2,085%
EPS CAGR (3Y) 3.4% – 83.1%
Operating cash flow growth (1Y) 28.4% – -44.9%
Operating cash flow CAGR (3Y) -4.4% – -1.1%
Free cash flow growth (1Y) 38.7% – -84.6%
Free cash flow CAGR (3Y) -4.9% – -35.0%

Profitability

14 metrics
MetricHSICMDLNAMRX
Gross margin 31.6% 25.7% 40.2%
EBITDA margin 7.6% 9.2% 21.5%
Operating margin 5.2% 5.7% 15.0%
Pretax margin 4.2% 3.6% 6.9%
Net margin 3.1% 2.7% 4.2%
FCF margin 4.1% 6.2% 1.2%
Operating cash flow margin 5.0% 7.8% 5.7%
Return on equity 11.6% 4.6% 74.3%
Return on assets 3.9% 2.2% 4.6%
Return on invested capital 7.3% 4.3% 14.3%
Return on capital employed 9.0% 4.8% 14.1%
Asset turnover 1.2x 0.8x 0.7x
Cash conversion (OCF / net income) 1.6x 2.7x 1.0x
Stock comp / revenue 0.3% 0.4% 1.2%

Financial Health

11 metrics
MetricHSICMDLNAMRX
Debt / assets 30.6% 31.3% 59.2%
Debt / equity 0.9x 0.6x 5.9x
Net debt / EBITDA 3.2x 3.2x 4.3x
Debt / FCF 6.3x 6.6x 81.2x
Liabilities / assets 66.8% 51.7% 89.9%
Equity / assets 33.2% 48.3% 10.1%
Interest coverage 4.3x – –
Current ratio 1.3x 4.0x 1.9x
Quick ratio 0.6x 2.4x 1.1x
Cash ratio 0.1x 1.2x 0.1x
Altman Z-score 2.65 2.70 1.96

Shareholder Returns

7 metrics
MetricHSICMDLNAMRX
Dividend yield – – –
Net buyback yield 6.8% -13.6% 0.0%
Shareholder yield 6.8% -13.6% 0.0%
Payout ratio (earnings) 6.8% – –
Payout ratio (FCF) 5.4% – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusHSICMDLNAMRX
Forward P/E 14.6xFY2026 26.5xFY2026 21.4xFY2026
EPS, next fiscal year $5.89FY2026 $1.49FY2026 $1.00FY2026
EPS growth, next FY +18.5%FY2026 +4.2%FY2026 +20.5%FY2026
EPS growth, the year after +5.9% +9.4% +26.0%
Revenue, next fiscal year $13.36BFY2026 $32.69BFY2026 $3.30BFY2026
Revenue growth, next FY +1.3%FY2026 +15.0%FY2026 +9.1%FY2026
Revenue growth, the year after +4.6% +8.2% +12.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersHSICMDLNAMRX
Held by institutions 100.0% 57.1% 51.0%
Institutions holding 566 409 310
Change in shares held, QoQ +2.1% +17.9% +1.3%
Institutions buying 244 322 182
Institutions selling 217 69 86
Buyers to sellers 1.12 4.67 2.12

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

HSICMDLNAMRX
HSIC 1.00 0.40 0.18
MDLN 0.40 1.00 0.19
AMRX 0.18 0.19 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, HSIC, MDLN and AMRX?

Medline (MDLN) is the largest by market capitalisation: Henry Schein (HSIC) $9.36B, Medline (MDLN) $34.27B, Amneal Pharmaceuticals (AMRX) $7.14B.

Which stock is cheaper, HSIC, MDLN and AMRX?

Henry Schein (HSIC) trades on the lowest price-to-earnings ratio (Henry Schein (HSIC) 22.2x, Medline (MDLN) 40.8x, Amneal Pharmaceuticals (AMRX) 53.6x). On next year's consensus earnings, Henry Schein (HSIC) is cheapest (Henry Schein (HSIC) 14.6x, Medline (MDLN) 26.5x, Amneal Pharmaceuticals (AMRX) 21.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Amneal Pharmaceuticals (AMRX) grew revenue fastest over the trailing twelve months: Henry Schein (HSIC) +6.2%, Amneal Pharmaceuticals (AMRX) +8.9%.

Which company is more profitable?

Amneal Pharmaceuticals (AMRX) has the highest net margin (Henry Schein (HSIC) 3.1%, Medline (MDLN) 2.7%, Amneal Pharmaceuticals (AMRX) 4.2%). On return on invested capital, Amneal Pharmaceuticals (AMRX) leads (Henry Schein (HSIC) 7.3%, Medline (MDLN) 4.3%, Amneal Pharmaceuticals (AMRX) 14.3%).

Which stock has performed better?

Over the past year Amneal Pharmaceuticals (AMRX) returned the most: Henry Schein (HSIC) +17.6%, Amneal Pharmaceuticals (AMRX) +85.6%. Over five years, Amneal Pharmaceuticals (AMRX) compounded fastest (Henry Schein (HSIC) +1.7%/yr, Amneal Pharmaceuticals (AMRX) +32.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Henry Schein (HSIC) has been the steadiest (Henry Schein (HSIC) 25.2%, Medline (MDLN) 47.8%, Amneal Pharmaceuticals (AMRX) 34.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, HSIC, MDLN and AMRX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Amneal Pharmaceuticals (AMRX) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.